Recomp Stack Retatrutide + Tesamorelin + Ipamorelin · Research Peptide Stack — Canada
The Recomp Stack combines Retatrutide, Tesamorelin and Ipamorelin for body-composition research. Fat-loss hormone research plus both growth-hormone signals.
Body-composition research looks at two things at once: fat stores and lean tissue. Retatrutide covers the hormone side that controls appetite and blood sugar. Tesamorelin and ipamorelin cover growth hormone, which researchers study for its role in body composition, from its two separate signals.
$222.00 CAD ($15.00 less than buying separately, $237.00) — In stock. Flat $20.00 shipping, free over $300.00.
- Retatrutide 10mg — $89.00
- Tesamorelin 10mg — $89.00
- Ipamorelin 10mg — $59.00
Reviewed 2026-11-08 by the Peak Peptides research team. 6 studies cited.
How they fit together
Hormone signals
Gut hormones that regulate appetite and blood sugar.
- Retatrutide: Activates the GLP-1, GIP and glucagon receptors at once.
Fat stores
Where the body keeps fat, especially deep visceral fat.
- Retatrutide: Body weight and liver fat in phase 2 and 3 trials.
- Tesamorelin: Visceral and liver fat in randomised trials.
Two growth-hormone signals
GHRH and ghrelin, two routes to the same release.
- Tesamorelin: A stabilised GHRH analogue that activates the GHRH receptor.
- Ipamorelin: Activates the ghrelin receptor; described in 1998 as the first selective GH secretagogue.
Growth hormone and IGF-1
Growth hormone raises IGF-1, the marker researchers track.
- Tesamorelin: IGF-1 levels measured in randomised trials.
- Ipamorelin: Growth-hormone release modelled in a 1999 human study.
How they compare
| Compound | What it is | Pathway studied | Studied in | Evidence | Key study |
|---|---|---|---|---|---|
| Retatrutide | Triple-agonist peptide | GLP-1, GIP and glucagon receptors | Body weight, Glucose control, Liver fat | Phase 2 and 3 human trials | Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. (2026), PMID 42814954 |
| Tesamorelin | GHRH analogue | GHRH receptor, growth hormone and IGF-1 | Visceral fat, Liver fat, GH signalling | Randomised human trials | Metabolic effects of a growth hormone-releasing factor in patients with HIV. (2007), PMID 18057338 |
| Ipamorelin | Selective growth-hormone secretagogue | Ghrelin receptor and growth hormone | Selective GH release, Bone growth, Gut motility | Animal and early human studies | Ipamorelin, the first selective growth hormone secretagogue. (1998), PMID 9849822 |
Key studies
- Retatrutide: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. (phase 3 trial, 2026). 80-week randomised trial in 2,339 adults with obesity.
- Retatrutide: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (phase 2 trial, 2023). 48-week randomised trial in 338 adults.
- Tesamorelin: Metabolic effects of a growth hormone-releasing factor in patients with HIV. (phase 3 trial, 2007). 26-week randomised trial in 412 adults with HIV.
- Tesamorelin: Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. (randomised trial, 2014). 6-month trial of visceral and liver fat in 50 adults.
- Ipamorelin: Ipamorelin, the first selective growth hormone secretagogue. (preclinical, 1998). Growth-hormone release without notable ACTH or cortisol change.
- Ipamorelin: Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. (clinical, 1999). Growth-hormone response modelled in healthy volunteers.
Related stacks
- GH Stack: Ipamorelin + Tesamorelin, $138.00 CAD
- Metabolic Stack: Retatrutide + Tesamorelin + MOTS-c, $252.00 CAD
- Metabolic Stack · Ipamorelin: Retatrutide + Ipamorelin + MOTS-c, $222.00 CAD
Related research
- Retatrutide Canada Approval: TRIUMPH Phase 3 Results 2026
- Tesamorelin vs Ipamorelin vs Sermorelin: Receptors, Evidence and Regulatory Status Compared
- Do Peptides Cause Cancer? What the Research Actually Shows (2026)
Recomp Stack, answered
What is the Recomp Stack?
The Recomp Stack combines Retatrutide, Tesamorelin and Ipamorelin for body-composition research. Fat-loss hormone research plus both growth-hormone signals.
Why are Retatrutide, Tesamorelin and Ipamorelin researched together?
Body-composition research looks at fat and lean tissue together. Retatrutide covers the appetite and glucose hormones, while tesamorelin and ipamorelin cover the growth-hormone axis from its two separate signals, GHRH and ghrelin.
How much does the Recomp Stack cost?
The Recomp Stack is $222.00 CAD, $15.00 less than buying Retatrutide, Tesamorelin and Ipamorelin separately ($237.00). Shipping is a flat $20.00 across Canada, free on orders over $300.00.
Where can I buy the Recomp Stack in Canada?
Peak Peptides ships the Recomp Stack from Toronto to every province and territory, tracked and in discreet packaging. Orders paid before 12 PM (Toronto time) are dispatched the same day; delivery takes 1–3 business days in Ontario and 3–5 elsewhere in Canada.
Recomp Stack or Metabolic Stack?
Both include retatrutide and tesamorelin. Recomp adds ipamorelin for a second growth-hormone signal; Metabolic adds MOTS-c for cell-energy research instead.
How is each compound tested?
Third-party tested, >98% purity, COA published. Each product page links the certificate of analysis for the current batch.
How is the Recomp Stack supplied?
Each compound comes as a lyophilised powder in its own sealed vial, for laboratory research use only. Store at −20°C, dry and dark, and keep sealed and lyophilised until use.